Raptiva

Raptiva

a trademark for efalizumab.
References in periodicals archive ?
On April 8th, 2009, Genentech and Roche announced the voluntary withdrawal of Raptiva from the U.
San Francisco CA) is pulling its psoriasis drug Raptiva from the U.
Biotech firm Genentech Inc, recently acquired by Roche Holdings AG for $47 billion, said Wednesday that it has pulled its psoriasis drug Raptiva from the U.
In the 1980's we had the Tylenol scare; earlier in this decade Vioxx and other similar drugs were grabbing headlines with their safety related problems; and now the problems and health risks of Raptiva are reaching a boiling point.
Nice (The National Institute for Health and Clinical Excellence) has issued guidance for the use of the targeted biological therapies Enbrel (etanercept) and Raptiva (efalizumab) to treat adult patients with plaque psoriasis.
But it is claimed Raptiva, approved by the European Union yesterday, has few side-effects and provides long-term relief.
Also posing competition are Johnson & Johnson's Remicade and Genentech's Raptiva.
Enbrel, a biologic drug therapy initially approved for psoriatic arthritis, and Raptiva, have recently been approved for psoriatic skin disease.
San Francisco, CA) Xolair and RAPTIVA antibody products.
The withdrawal of Genentech/Merck Seronos Raptiva (efalizumab) in Q1 2009 is predicted to benefit both Abbotts Humira (adalimumab) and Johnson & Johnsons Stelara (ustekinumab), but safety will be even more key to regulators now.
April 10 /PRNewswire/ -- On April 8th, 2009, Genentech and Roche announced the voluntary withdrawal of Raptiva (efalizumab, marketed by Genentech/Roche and Xoma) from the US market.
The FDA has announced labeling changes, including a boxed warning, to highlight the risks of life-threatening infections with the use of Raptiva (efalizumab).